Reduction of APL antibodies by immunoadsorption may be a lifesaving therapy for the management of DAH with high titer of APL antibodies. Autologous HSCT may be a valid treatment option in patients with primary APS and no response to standard immunosuppressive therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737408 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2019000465 | DOI Listing |
Publication Analysis
Top Keywords
apl antibodies
8
immunoadsorption autologous
4
autologous transplantation
4
transplantation life-threatening
4
life-threatening primary
4
primary antiphospholipid
4
antiphospholipid syndrome
4
syndrome reduction
4
reduction apl
4
antibodies immunoadsorption
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!